louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06608797: Testing the Feasibility of Computer-based Cognitive Training in Individuals with Multiple Sclerosis Living in the Community
Official title: Testing the Feasibility of Computer-based Cognitive Training in Individuals with Multiple Sclerosis Living in the Community
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Multiple Sclerosis
Keywords: learning, memory, cognitive training
Lead sponsor: Kessler Foundation
Sponsor class: OTHER
First posted: 2024-09-23
Enrollment: 40
Sex: ALL
Minimum age (years): 19
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Cognitive impairments are common in multiple sclerosis (MS) diagnosed both at the onset and throughout the disease course. Poor cognitive abilities have been associated with poor outcomes such as higher levels of unemployment, poor quality of life, driving difficulties among others. Learning and memory are a common cognitive deficit. This computer-based cognitive training is a 10-session treatment proven to be effective in ameliorating learning and memory in individuals with MS across 3 realms of functioning: objective cognitive performance, daily life activities and neuroimaging. Despite this strong efficacy, as well as the recent clinical application of this computer-based cognitive training across the world, recent in-person studies have highlighted that transportation to the clinic to complete treatment sessions is a significant obstacle to clinical use of this effective treatment. To address this limitation, the proposed pilot study will test the efficacy of the computer-based cognitive training administered remotely via zoom health in persons with multiple sclerosis.


Eligibility criteria: Inclusion Criteria:

* English as primary language
* Diagnosis of multiple sclerosis

Exclusion Criteria:

* Most recent exacerbation within one month
* Other Neurological History: head injury, stroke, seizures, or any other significant neurological history will not be included in the study
* Individuals with an active diagnosis of Major Depressive Disorder, Schizophrenia, Bipolar Disorder I or II will be excluded from the study.
* Poor Visual Acuity (corrected vision in worse eye \&amp;lt; 20/60), diplopia, or nystagmus
* Inability to understand directions and following one, two, and three step commands
* Intact New Learning and Memory: Only individuals that show impaired performance on a memory test will be included in the study

Primary outcomes:
measure: California Learning Verbal Test III
timeFrame: Primary outcome will be assessed at baseline (1 week before training start) and immediate follow-up (within 1 week after training completion)
Secondary outcomes:
measure: Ecological Memory Simulations
timeFrame: Secondary outcome will be assessed at baseline (1 week before training start) and immediate follow-up (within 1 week after training completion)
Other outcomes:
Locations:
city: East Hanover
country: United States
facility: Kessler Foundation
state: New Jersey
Study officials:
References:
Clinical trial NCT01298297: Efficacy of Buprenorphine for Treatment of Acute Pain
Official title: Comparison of Sublingual Buprenorphine With Intravenous Morphine Sulfate in Treatment of Acute Pain Due to Long Bone Fracture
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE4
Conditions: Acute Pain
Keywords: Buprenorphine, acute pain, analgesia
Lead sponsor: Tehran University of Medical Sciences
Sponsor class: OTHER
First posted: 2011-02-17
Enrollment: 80
Sex: ALL
Minimum age (years): 16
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to determine whether sublingual buprenorphine is effective in the treatment of acute pain in adult patients with extremity bone fractures


Eligibility criteria: Inclusion Criteria:

Clinical diagnosis of extremity bone fracture Age\>16 years Acute pain of score 3 or greater on numerical rating scale

Exclusion Criteria:

Long term use of opium or opioids/dependence Previous administration of analgesic Known sensitivity to opioids Pregnant women History of medical problems (liver, kidney, heart, hematologic)

Primary outcomes:
measure: Change in pain severity/score
timeFrame: After 60 min
Secondary outcomes:
measure: Need for rescue analgesia
timeFrame: After 60 min
measure: Occurrence of adverse events
timeFrame: During 60 min
Other outcomes:
Locations:
city: Tehran
country: Iran, Islamic Republic of
facility: Emergency Department, Imam Hospital
Study officials:
References:
Clinical trial NCT02028897: Comparison of Alternative Embryo Culture Systems
Official title: Comparison of Alternative Embryo Culture Systems
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Infertility
Keywords: In vitro fertilization
IVF
Embryo culture
Blastocyst transfer
Lead sponsor: Fertility Center of Las Vegas
Sponsor class: INDUSTRY
First posted: 2014-01-07
Enrollment: 0
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study will compare two alternative embryo culture systems. Embryos from each patient will be randomly assigned to one of two systems. One group will be cultured conventionally in oil-covered droplets in dishes. The other group will be assigned to an enclosed system.

Detailed description: Qualifying and consenting IVF patients will have approximately half of their developing embryos cultured in droplets covered with oil. The other approximate half of their embryos will be cultured in small enclosed containers. Embryo assignments will be at random. Regardless of culture system, all embryos will be cultured from the bipronuclear stage to the blastocyst stage in the same (Global) media, without the usual refreshing of media on day 3.

Eligibility criteria: Inclusion Criteria:

* Female age 18 to 40, seeking IVF treatment
* Ability to understand English (to obtain informed consent)
* Use of an oocyte donor, sperm donor, gestational carrier, and/or genetic testing (with blastocyst biopsy only) are allowed.

Exclusion Criteria:

* Diminished ovarian reserve as evidenced by either elevated cycle day 3 follicle stimulating hormone (FSH) level (≥10 IU/L) or low antral follicle count (\<8 antral follicles)
* Fewer than five (5) bipronuclear oocytes
* Day 3 embryo biopsy for any reason
* No minors may enroll

Primary outcomes:
measure: Blastulation rate
timeFrame: 5 days (sixth day of embryo development)
Secondary outcomes:
measure: Blastocyst morphology
timeFrame: 5 days (sixth day of development)
measure: IVF outcome
timeFrame: 7 weeks post-transfer
Other outcomes:
Locations:
city: Las Vegas
country: United States
facility: Fertility Center of Las Vegas
state: Nevada
Study officials:
affiliation: Fertility Center of Las Vegas
name: Bruce Shapiro, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT05948397: To Use the Combined Version of ICIQ-SF and Quality of Life Scale in Mixed Urinary Incontinence
Official title: To Use the Combined Version of ICIQ-SF and Quality of Life Scale in Mixed Urinary Incontinence
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Incontinence, Urge
Incontinence Stress
Quality of Life
Lead sponsor: Koç University
Sponsor class: OTHER
First posted: 2023-07-17
Enrollment: 100
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Females with mixed urinary incontinence

Brief summary: The goal of this observational study is detecting the dominant component of mixed urinary incontinence via a combined version of ICIQ-SF and quality of life scale. The main question it aims to answer is:

1. Which component (urgency or stress) urinary incontinence bothers the patient more?

Detailed description: Female patients with mixed urinary incontinence will be given a combined version of ICIQ-SF and quality of life scale on the first visit. Additionally, a bladder diary and 1-hour pad test will be performed on the same visit. After deciding the appropriate treatment, on the 1-month visit (second visit) the same tests will be repeated and scores will be compared.

Eligibility criteria: Inclusion Criteria:

* Female patients above 18 years old with mixed urinary incontinence

Exclusion Criteria:

* Non-Turkish speakers
* Poor conscious level
* Immobile patients

Primary outcomes:
measure: International Consultation on Incontinence Questionnaire Short Form
timeFrame: 1 month
measure: Pad test
timeFrame: 1 month
measure: Bladder diary
timeFrame: 1 month
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03600597: Construct Validity and Reliability SCUES
Official title: Construct Validity and Reliability of the Selective Control of the Upper Extremity Scale in Children With Cerebral Palsy
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cerebral Palsy
Upper Extremity Dysfunction
Lead sponsor: Gazi University
Sponsor class: OTHER
First posted: 2018-07-26
Enrollment: 33
Sex: ALL
Minimum age (years): 3
Maximum age (years): 18
Standard ages: CHILD
ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Children with Unilateral Cerebral Play

Brief summary: The aim of the study was to determine construct validity, discriminant validity and intra- and interrater reliability of the Selective Control of the Upper Extremity Scale (SCUES).

Detailed description: This study included children diagnosed with unilateral cerebral palsy. Children's upper extremity-selective motor controls were evaluated by video recording. Manual Ability Classification System and Taylor Hand Function Test were used to determine upper extremity functions

Eligibility criteria: Inclusion Criteria:

* Ages between 3-18 years
* Diagnosed as Cerebral Palsy (Hemiplegia)

Exclusion Criteria:

* Participants with an unstable situation regarding their tonus-regulating medications
* Participants had a botulinum toxin injection within the last 6 months, or any surgical correction within the last year

Primary outcomes:
measure: Selective Control of the Extremity Scale
timeFrame: 10 minutes
Secondary outcomes:
measure: Jebsen Taylor Hand Function Test
timeFrame: 20 minutes
Other outcomes:
Locations:
city: Ankara
country: Turkey
facility: Gazi University
state: Yeni̇mahalle
Study officials:
affiliation: Study chair
name: Bulent Elbasan
role: STUDY_CHAIR
References:
Clinical trial NCT03552497: The Potential of Radiomics to Differentiate Between Malignant and Benign Bosniak 3 Renal Cysts.
Official title: The Potential of Radiomics to Differentiate Between Malignant and Benign Bosniak 3 Renal Cysts.
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Renal Cyst Complex
Keywords: Radiomics
Bosniak classification
Renal cell carcinoma
Medical imaging
Lead sponsor: Maastricht University
Sponsor class: OTHER
Collaborators: name: University of California, San Francisco
name: Stanford University
name: Erasmus Medical Center
name: Memorial Sloan Kettering Cancer Center
name: University of Sao Paulo General Hospital
name: University Hospital, Aachen
First posted: 2018-06-12
Enrollment: 500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients with renal cysts classified as bosniak 3 in one of the collaborating institutes.

Brief summary: More than 200,000 new cases of renal cancer are diagnosed in the world each year, with more than 63,000 new cases in Europe alone. Of those, renal cell carcinoma (RCC) is the most common type in adults, making up more than 90% of the cases. Deciding on the benign or malignant nature of some RCC on the basis of medical images (CT, MRI, US) is an issue, which often leads to unnecessary surgery, morbidity and costs.

A categorization for renal cysts was introduced in the late 1980s known as the Bosniak classification. The Bosniak classification system classifies them into groups that are benign (I and II) and those that need surgical resection (III and IV), based on specific imaging features. However, defining the malignancy of category III lesions still remains a challenge. Though Bosniak classification for renal cysts is used worldwide and underwent a number of modifications, Bosniak III cysts still have almost a 1:1 chance of being malignant. So the problem is that approximately half of the Bosniak category III cystic lesions prove to be benign after surgery.

The proposed project aims to develop a quantitative image analysis (QIA) based multifactorial decision support system (mDSS) capable of classifying renal cysts with high accuracy into benign or malignant status, thus reducing the amount of unnecessary surgeries performed. Using standard-of-care CT images and clinical parameters, the customized DSS will then guide experts in planning a safe and effective diagnostic and treatment strategy for all RCC patients.


Eligibility criteria: Inclusion Criteria:

* Patients who underwent contrast-enhanced CT-Scan, with radiological findings suggestive of Bosniak 3 renal cyst and have available results for pathology analysis of the cyst.

Exclusion Criteria:

* CT-Scans that are reformatted or secondary.

Primary outcomes:
measure: malignancy classifier
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
city: Maastricht
country: Netherlands
facility: Maastricht University Medical Center
state: Limburg
Study officials:
References:
Clinical trial NCT01594697: Metformin in Pregnancy in Women With Polycystic Ovary Syndrome
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Polycystic Ovary Syndrome
Lead sponsor: Catholic University of the Sacred Heart
Sponsor class: OTHER
First posted: 2012-05-09
Enrollment: 60
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 40
Standard ages: ADULT
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The study provide a detailed longitudinal evaluation of the gluco-insulinemic assessment of pregnant PCOS women under metformin treatment. 47 non diabetic Polycystic Ovary Syndrome (PCOS) women became pregnant during metformin treatment and continued taking the drug during gestation. An oral glucose tolerance test and euglycaemic hyperinsulinaemic clamp were performed at each trimester of gestation.


Eligibility criteria: Inclusion Criteria:

* age 18-40 yr,
* metformin treatment for at least 3 months before entering the pregnancy,
* gestational age between 5 and 12 wk

Exclusion Criteria:

* diabetes mellitus
* significant liver or renal impairment
* neoplasms and other endocrine diseases
* the use of drugs other than metformin able to interfere with glucose and insulin metabolism.

Primary outcomes:
measure: incidence of gestational diabetes
Secondary outcomes:
measure: rate of spontaneous abortion
measure: number of hypertensive disorders
measure: number of live births
measure: number of newborns with macrosomia
measure: incidence of delivery by caesarian section
Other outcomes:
Locations:
city: Rome
country: Italy
facility: Catholic University of Sacred Heart
Study officials:
References:
citation: Romualdi D, De Cicco S, Gagliano D, Busacca M, Campagna G, Lanzone A, Guido M. How metformin acts in PCOS pregnant women: insights into insulin secretion and peripheral action at each trimester of gestation. Diabetes Care. 2013 Jun;36(6):1477-82. doi: 10.2337/dc12-2071. Epub 2013 Jan 11.
Clinical trial NCT01196897: Evaluation of the Next Generation WATCHMAN LAA Closure Technology in Non-Valvular AF Patients (EVOLVE)
Official title: Evaluation of the Next Generation WATCHMAN LAA Closure Technology in Non-Valvular AF Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Atrial Fibrillation
Keywords: Atrial fibrillation
Stroke
Warfarin
Coumadin
TIA
Trans Ischemic Attack
Lead sponsor: Boston Scientific Corporation
Sponsor class: INDUSTRY
First posted: 2010-09-09
Enrollment: 69
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This study will evaluate the next generation WATCHMAN Left Atrial Appendage (LAA) Closure Device as implanted in patients with non-valvular atrial fibrillation (AF) with a CHADS2 stroke risk stratification score of 1 or greater. This is a prospective, non-randomized study to evaluate the initial use of the next generation WATCHMAN Device.


Eligibility criteria: Key Inclusion Criteria:

* Paroxysmal, persistent, or permanent non-valvular atrial fibrillation
* Eligible for long-term Warfarin therapy;
* Eligible to come off Warfarin therapy if the LAA is sealed
* Calculated CHADS2 score of 1 or greater

Key Exclusion Criteria:

* New York Heart Association Class IV Congestive Heart Failure
* Recent MI (within 3 months)
* ASD and/or atrial septal repair or closure device
* Resting heart rate \>110 bpm
* Has an implanted mechanical valve prosthesis
* Left atrial appendage is obliterated
* Has undergone heart transplantation
* Has symptomatic carotid disease
* Contraindicated for aspirin
* LVEF \< 30%
* Cardiac Tumor

Primary outcomes:
measure: Successful implantation of the next generation WATCHMAN device without the occurance of life-threatening events caused by the device and/or procedure.
timeFrame: 12-Months
measure: Device Success
timeFrame: Implant through 45-Days
Secondary outcomes:
Other outcomes:
Locations:
city: Prague
country: Czech Republic
facility: NA Homolce Hospital
city: Regensburg
country: Germany
facility: Krankenhaus der Barmherzige Bruder
state: Bayern
city: Frankfurt
country: Germany
facility: Sankt Katharinen Hospital / Cardiovasculares Centrum
Study officials:
affiliation: Na Homolce Hospital
name: Vivek Reddy, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01446497: Efficacy and Safety Study of Combigan and 0.5% Timoptic in Normal Tension Glaucoma
Official title: Randomized, Multicenter, Open-label, Parallel Group Study to Evaluate Efficacy and Safety of Combigan(Brimonidine/Timolol) and 0.5% Timoptic(Timolol) Ophthalmic Solutions in Normal Tension Glaucoma Patients
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: Normal Tension Glaucoma
Keywords: Normal tension glaucoma
Antiglaucoma ophthalmic solution
Brimonidine
Timolol
Combination drugs
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
First posted: 2011-10-05
Enrollment: 22
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Purpose To evaluate efficacy and safety of combigan(Brimonidine/Timolol) and 0.5% Timoptic (Timolol) ophthalmic solutions in normal tension glaucoma patients.

Detailed description: * Normal tension glaucoma (NTG) is the major type of glaucoma in Korea. (over 90% of glaucoma type)
* Brimonidine (selective alpha 2 adrenergic agonist): neuroprotection effect by suppression of aqueous humor production and increasement of uveoscleral outflow
* Timolol (non selective beta blocker): suppression effect of aqueous humor production
* Combigan (fixed combination of brimonidine \& timolol): more lowering effect of intraocular pressure and enhancing the compliance of glaucoma patients

Eligibility criteria: Inclusion Criteria:

* over 18 years old
* baseline IOP under 22 mmHg,both anterior chamber angle \> Grade 3\~4 by Shaffer grading system

Exclusion Criteria:

* IOP over 22 mmHg by Goldmann applanation tonometer
* other types of glaucoma except open angle
* other IOP lowering treatment
* chronic or recurrent Hx. of ocular inflammation
* using contact lens
* any other ocular disease that could affect visual field examination (diabetic retinopathy, macular disease, uveitis, scleritis, optic neuritis, anterior ischemic optic neuropathy)
* intraocular or glaucoma surgery within 6 months
* Hx. of allergic reaction to timolol or brimonidine
* bronchial asthma
* moderate to severe chronic obstructive pulmonary disease
* heart failure
* 2\~3 degree A-V block,
* MAO inhibitor use
* anti depressant use
* untreated pheochromocytoma
* pregnant

Primary outcomes:
measure: Change from baseline in intraocular pressure at 12 weeks
timeFrame: 12 weeks after the initial treatment
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Seoul National University Hospital
Study officials:
affiliation: Seoul National University Hospital
name: Ki Ho Park, M.D, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06922097: Treating Intraoperative Bradycardia in Non-cardiac Surgery Patients With Atropine at Heart Rates Below 60 Versus 30 Beats Per Minute and Norepinephrine Requirements
Official title: Treating Intraoperative Bradycardia in Non-cardiac Surgery Patients With Atropine at Heart Rates Below 60 Versus 30 Beats Per Minute and Norepinephrine Requirements: the Randomized RAPID Trial
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Intraoperative Bradycardia
Lead sponsor: University of Hamburg-Eppendorf
Sponsor class: OTHER
First posted: 2025-04-10
Enrollment: 186
Sex: ALL
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The RAPID trial is a randomized, single-center trial investigating whether giving atropine at heart rates below 60 beats per minute versus giving atropine only at heart rates below 30 beats per minute reduces the amount of norepinephrine needed to keep MAP above 65 mmHg in non-cardiac surgery patients with intraoperative bradycardia.


Eligibility criteria: Inclusion Criteria: Consenting patients ≥50 years scheduled for elective non-cardiac surgery with general anesthesia that is expected to last ≥60 minutes with at least two of the following risk criteria for developing acute kidney injury:

* Age ≥65 years
* American Society of Anesthesiologists physical status III or IV
* Chronic arterial hypertension
* Diabetes mellitus requiring medication
* Intraabdominal surgery
* Preoperative renal insufficiency (serum creatinine ≥1.2 mg/dL)

Exclusion Criteria:

Patients with the following exclusion criteria: contraindication for atropine administration (e.g., myasthenia gravis, high-grade aortic stenosis, high-grade coronary artery disease, glaucoma, paralytic ileus, prostatic hypertrophy); renal replacement therapy within the previous 3 months; chronic kidney disease with an estimated glomerular filtration rate \<20 mL/min/1.73 m2; pregnancy.

Primary outcomes:
measure: Average norepinephrine infusion rate
timeFrame: Perioperative
Secondary outcomes:
measure: Time-weighted average MAP <65 mmHg
timeFrame: Perioperative
measure: Time-weighted average heart rate <60 bpm
timeFrame: Perioperative
measure: Time-weighted average MAP >110 mmHg
timeFrame: Perioperative
measure: Time-weighted average heart rate >100 bpm
timeFrame: Perioperative
Other outcomes:
measure: Incidence of acute kidney injury
timeFrame: Within the first 3 postoperative days
measure: Incidence of delirium
timeFrame: Within the first 3 postoperative days
measure: Incidence of urinary retention
timeFrame: Within the first 3 postoperative days
measure: Incidence of central anticholinergic syndrome
timeFrame: Within the first 3 postoperative days
measure: Incidence of acute angle-closure glaucoma
timeFrame: Within the first 3 postoperative days
Locations:
city: Hamburg
country: Germany
facility: University Medical Center Hamburg-Eppendorf
Study officials:
affiliation: University Medical Centre Hamburg-Eppendorf
name: Alina Bergholz, MD
role: PRINCIPAL_INVESTIGATOR
References: